Reports

Six Month Report of 16 Key Findings

Anabolic Therapy for Combined AA and EDS

Update Report 2019: Hormones and Pain Care – “The Way Forward”

 

Supportive Bibliographies

Bibliography in Support of AA Protocol

Bibliography of Articles for Hormone Report

Bibliography of Articles on Neurosteroids

 

Bulletins

Welcome to the Arachnoiditis Bulletins

Bulletin 1 – Explanations and Definitions You Must Know – Revised 3/18

Bulletin 2 – Arachnoiditis No Longer A Rare Disease – Revised 3/18

Bulletin 3 – A Brief History of Arachnoiditis – Revised 10/18

Bulletin 4 – Causes of Arachnoiditis – Revised 10/18

Bulletin 5 – Seven Facts About Neuroinflammation That You Should Know – Revised 7/19

Bulletin 6 – Major Symptoms and Harms of AA – Revised 11/18

Bulletin 7 – Natural Course and Outcome of AA – Revised 11/18

Bulletin 8 – The Diagnosis of AA – Revised 11/18

Bulletin 9 – 3 Keys to Treating Lumbar-Sacral Adhesive Arachnoiditis – Revised 6/19

Bulletin 10 – Treatment of Adhesive Arachnoiditis – Revised 7/19

Bulletin 11 – Arachnoiditis Categorization – Revised 7/19

Bulletin 12 – Emergency Treatment for Arachnoiditis

Bulletin 13 – Screening for AA

Bulletin 14 – How to Safely Take Ketorolac and Methylprednisolone – Revised 7/19

Bulletin 15 – Getting Started To Treat and Survive AA

Bulletin 16 – Protocol for Emergency Treatment of Suspected Lumbar-Sacral Arachnoiditis – June 2019

Bulletin 17 – Best Treatment for AA – Revised 3/18

Bulletin 18 – Therapeutic Trials – What are they and why are they essential? – Revised 6/19

Bulletin 19 – Equivocal or Inconclusive MRI – Revised 8/19

Bulletin 20 – Neuroinflammation & Neurodegeneration – Revised 7/18

Bulletin 21 – Self-Help With Non-Prescription Drugs – Revised 7/19

Bulletin 22 – Stem Cells and Electric Stimulators

Bulletin 23 – Most Common Cause of Centralized Intractable Pain (CIP)

Bulletin 24 – Anabolism and Catabolism – You Must Know the Difference

Bulletin 25 – Arachnoiditis Patients Must Have a Compounding Pharmacy